Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPRING
NCT07517289Phase 1Not yet recruiting
- Sponsor
- EIPICO
- Start
- Apr 2026
- Primary completion
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 1, randomised, open-label trial of enoxaparin in venous thromboembolism (VTE) (2 arms), sponsored by EIPICO. Primary endpoints: Maximum observed anti-Factor Xa activity, Area under the effect curve for anti-Factor Xa activity from time zero to time t and 2 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
enoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT07517289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07517289.